Company intelligence / Profile preview

Cleo Diagnostics

Melbourne, Victoria, Australia

Ownership: Private
Development stage: Phase 2

Overview

Cleo Diagnostics has developed a minimally invasive blood test using antibodies to detect ovarian cancer-specific biomarkers in serum. The lead product—the pre-surgical triage test—has completed alpha testing with strong results differentiating malignant from benign gynecological conditions. The company aims to improve early detection rates for ovarian cancer and has entered collaborations to accelerate validation and commercialization.

Therapeutic areas: Oncology
Modalities: AntibodyDiagnostic test
Industry: Protein Biomarker Diagnostics

Partnerships

University College London – collaboration for access to over 2,000 samples from the UKCTOCS biobank for validation studies

Beyond the preview

Go deeper on Cleo Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cleo Diagnostics.

Explore the full profile